Moreover, KCa3.1 channel blocker TRAM-34 reduces the severity of DSS-induced colitis and normalizes the expression of KCa3.1, NDPK-B, and Th1 cytokines in the mesenteric lymph node CD4+ T cells (Ohya et al., 2014). The gene discussed is CD4; the disease is colitis.